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O veractive bladder (OAB) is defined as urinary urgency,  usually accompanied by frequency and 
nocturia,  with or without urgency urinary inconti-
nence (UUI) [1].  
OAB is common among elderly women [2] and 
affects health-related quality of life [3].  The current 
pharmacological approach to OAB treatments involves 
many drugs,  mainly anti-muscarinic agents.  However,  
anti-muscarinic agents are associated with relatively 
high rates of adverse events such as dry mouth and con-
stipation.  In 2011,  mirabegron,  a β3-adrenoceptor 
agonist,  was developed for the treatment of OAB,  with 
a mechanism of action distinct from that of anti-mus-
carinics.  β3-adrenoceptor is responsible for promoting 
human detrusor relaxation and urine storage in the 
bladder [4-7].  Mirabegron demonstrated significant 
efficacy in treating the symptoms of OAB,  and had a 
low rate of adverse events.  The incidence of dry mouth 
is similar to that seen with a placebo,  and is between 
three- and five-fold less than that seen when tolterodine 
is used as an anti-muscarinic [8].  Several studies have 
shown that both mirabegron and anti-muscarinics 
improve OAB symptoms,  with no statistically signifi-
cant differences observed between the 2 treatments 
[9-12].
Although anti-muscarinic agents are used as the 
first-line therapy for OAB,  they may be accompanied 
by bothersome adverse effects,  leading to poor adher-
ence to the prescribed medications.  Specifically,  dry 
Acta Med.  Okayama,  2019
Vol.  73,  No.  5,  pp.  387-392
CopyrightⒸ 2019 by Okayama University Medical School.
http ://escholarship.lib.okayama-u.ac.jp/amo/Original Article
Comparison of Two Different Drugs for Overactive Bladder,  Solifenacin 
and Mirabegron:  A Prospective Randomized Crossover Study
Miyabi Inouea＊,  and Teruhiko Yokoyamab
aMiyabi Urogyne Clinic,  Okayama 700-0822,  Japan,  bYokoyama Urological Clinic,  Okayama 700-0975,  Japan
To assess the efficacy and safety of 2 drugs for overactive bladder (OAB),  solifenacin and mirabegron.  Forty-
seven female OAB patients were randomized into 2 groups.  Twenty-three patients were initially prescribed 
solifenacin for 4 weeks,  followed by mirabegron for 4 weeks (group S).  The other 24 patients were initially pre-
scribed mirabegron for 4 weeks,  followed by solifenacin for 4 weeks (group M).  Evaluations included clinical 
determination of the OAB symptom score (OABSS),  International Prostate Symptom Score (IPSS),  and Visual 
Analog Scale.  The IPSS significantly improved after the administration of solifenacin in both groups.  The 
OABSS significantly improved in both groups after 4 weeks.  In group M,  the OABSS after eight weeks was sig-
nificantly improved compared to that after 4 weeks.  However,  in group S,  it was not significantly improved.  
Twelve patients experienced adverse events during the solifenacin treatment,  while 2 patients experienced 
adverse events during the mirabegron treatment.  Both solifenacin and mirabegron led to improved OAB 
symptoms.  Switching from mirabegron to solifenacin significantly improved the OABSS.  However,  mirabe-
gron led to fewer adverse events than solifenacin.  We recommend that mirabegron be prescribed first for OAB 
patients.  If patients are not satisfied with mirabegron,  solifenacin should be used.
Key words:  overactive bladder,  randomized crossover study,  solifenacin,  mirabegron
Received November 27, 2018 ; accepted April 10, 2019.
＊Corresponding author. Phone & Fax : +81-86-223-1100
E-mail : uromiya@msn.com (M. Inoue)
Conflict of Interest Disclosures: No potential conflict of interest relevant 
to this article was reported.
mouth is the most common reason for discontinuation 
[10].  Considering this,  we must ask which drugs 
should be used first for OAB.  The answer is not yet 
clear.  We assessed the efficacy and safety of 2 drugs,  
solifenacin succinate and mirabegron,  in the treatment 
of OAB from a clinical point of view.
Material and Methods
Patients and study protocol. This study was con-
ducted with the approval of the Institutional Review 
Board of Okayama Rosai Hospital.  After written 
informed consent was obtained,  the subjects were reg-
istered and randomly divided into the following 2 
groups.  Patients were divided with using the envelope 
method.  The solifenacin-preceding group (group S) 
received 5 mg of solifenacin once daily for 4 weeks fol-
lowed by mirabegron 50 mg once daily for 4 weeks.  The 
mirabegron-preceding group (group M) received 50 mg 
of mirabegron once daily for 4 weeks followed by 
solifenacin 5 mg once daily for 4 weeks.  Patients were 
switched to the alternative treatment quickly,  meaning 
they had no drug clearance period.  The subjects 
enrolled in this study comprised 47 consenting female 
OAB patients who visited Okayama Rosai Hospital 
between April 2012 and March 2014 and satisfied the 
following conditions: 20 years old or older,  an OABSS 
of 3 or higher,  and urgency once or more per week 
[13].  They had not previously received treatment for 
OAB.  The exclusion criteria included patients with the 
presence of residual urine ≥ 50 ml,  neurogenic bladder,  
stress urinary incontinence,  mixed urinary inconti-
nence,  or contraindications for either drug.  Patients 
who did not visit the hospital were judged as having 
dropped out.
Pre- and post-operative evaluation. Evaluations 
included the clinical determination of the OABSS,  
International Prostate Symptom Score (IPSS),  Visual 
Analog Scale (VAS),  maximum flow rate (Qmax) and 
postvoid residual urine volume (PVR) before and after 
treatment.  IPSS is a questionnaire used for benign 
prostatic hypertrophy,  but it is also used for women and 
is useful for recognizing the presence or absence of 
dysuria.  The IPSS can be used to evaluate female lower 
urinary tract symptoms,  and the IPSS is well correlated 
with the OABSS [14].
A VAS of 0 corresponds to no symptoms,  and a VAS 
of 10 corresponds to severe symptoms.  PVR was mea-
sured by transabdominal ultrasonography.  After 
patients had taken both medications,  we asked them 
which drug they preferred,  and why they chose it.
Statistical analysis. Based on the data character-
istics,  the median (min-max) was calculated.  In terms 
of statistical analysis,  the Wilcoxon signed rank test was 
performed to compare data pre- and post-administra-
tion in each group.  The Mann-Whitney U test was used 
for inter-group comparisons.  P values of less than 0.05 
were considered significant.  Data analysis was carried 
out with the Statistical Package for Social Sciences 
(SPSS).
Results
Patients’ backgrounds. Of the 47 patients who 
registered,  23 patients were assigned to group S (S to 
M) and 24 patients were assigned to group M (M to S).  
Seven patients who did not visit the hospital and two 
patients who stopped taking the assigned drug due to 
adverse events could not be assessed and were excluded.  
Thirty-eight (80.9%) completed the two cross-over pro-
tocols (Fig. 1).  Table 1 shows pre-administration back-
ground factors for the 47 patients.  There were no sig-
nificant differences between the 2 groups.
Evaluation. Table 2 shows the change in the 
IPSS,  OABSS,  and VAS from pre- to post- administra-
tion and comparisons of the degree of change between 
the 2 groups.  The IPSS was significantly improved after 
the subjects received solifenacin.  After they received 
mirabegron,  the IPSS was also improved,  but not sig-
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Fig. 1　 Disposition of patients.
nificantly.  The OABSS was significantly improved in 
both groups after treatment.  There were no significant 
differences between the 2 groups.
In group M,  the OABSS after 8 weeks was signifi-
cantly improved compared to that after 4 weeks.  On the 
other hand,  in group S,  it was not significantly 
improved.  In group M,  the VAS values for urgency and 
incontinence were significantly improved after treat-
ment.  In addition,  the VAS values for urgency and 
incontinence after 8 weeks were significantly improved 
compared to those after 4 weeks.  In group S,  on the 
other hand,  they were not significantly improved.  
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Table 1　 Pre-administration background factors of patients in group S and group M
Group S (n=23) Group M (n=24) Inter-group
Age (years) 70.0 (34.0-84.0) 75.0 (42.0-88.0) 0.333
Subjective
 symptom
Total IPSS 8.0 (3.0-27.0) 9.0 (2.0-34.0) 0.814
OABSS 8.0 (5.0-12.0) 9.0 (5.0-15.0) 0.588
Objective
 symptom
Voiding volume (mL) 95.0 (20.0-215.0) 128.0 (79.0-208.0) 0.503
Max ﬂow rate (mL/sec) 12.0 (7.0-24.0) 16.9 (9.0-34.0) 0.570
Postvoid residual urine volume (mL) 0.0 (0.0-16.0) 0.0 (0.0-41.0) 0.918
Median (min-max). Pre-administration background factors were compared inter-group by the Mann-Whitney U test.
Table 2　 Change in IPSS,  OABSS and VAS from pre- to post- administration and comparisons of the degree of change among the 2 
groups
Baseline 4 weeks after 8 weeks after
Total IPSS
S-M 8.0 (3.0-27.0) 5.0 (0.0-23.0) 3.0 (0.0-35.0)
Intra-group 0.017＊ 0.531
M-S 9.0 (2.0-34.0) 6.5 (0.0-23.0) 4.0 (0.0-19.0)
Intra-group 0.100 0.001＊
Inter-group 0.814 0.300 0.385
OABSS
S-M 8.0 (5.0-12.0) 4.0 (0.0-14.0) 3.0 (0.0-11.0)
Intra-group ＜0.0001＊  0.494
M-S 9.0 (5.0-15.0) 6.0 (0.0-11.0)  3.5 (0.0-9.0)
Intra-group ＜0.0001＊ ＜0.0001＊
Inter-group 0.588 0.143 0.656
VAS
Urgency
S-M 5.0 (1.0-10.0) 5.0 (0.0-10.0) 4.3 (0.2-6.2)
Intra-group 0.055 0.362
M-S 5.0 (2.5-10.0) 5.0 (0.0-10.0) 2.5 (0.0-10.0)
Intra-group 0.009＊ 0.006＊
Inter-group 0.605 0.872 0.089
S-M 4.5 (0.0-9.0) 2.5 (0.0-10.0) 1.9 (0.0-5.0)
Intra-group 0.266 0.637
Incontinence M-S 5.0 (0.5-10.0) 2.0 (0.0-7.5) 1.0 (0.0-5.0)
Intra-group 0.001＊ 0.059
Inter-group 0.205 0.939 0.510
Median (min-max).  Intra-group: The changes pre- and post 4W-administration,  post 4W- and post 8W-administration were compared by the 
Wilcoxon singed rank test Inter-group: The changes pre- and post 4W-,  8W-administration were compared in each group by the Mann-
Whitney U test. ＊p＜0.05.
Qmax and PVR were not significantly changed between 
before and after treatment in both groups (data not 
shown).
Table 3 shows the VAS values for constipation and 
dry mouth; both conditions were worsened during the 
administration of solifenacin in both groups.  The 
details of these and other adverse events in both groups 
were as follows.  Twelve patients (26.0%) experienced 
adverse events during the solifenacin treatment.  Four 
patients complained of dry mouth,  3 patients com-
plained of difficulty with urination,  and 3 patients 
complained of constipation.  One patient had eczema,  
and one patient had itching.  On the other hand,  2 
patients experienced adverse events during mirabegron 
treatment.  One patient complained of itching.  The 
patient experienced itching even during the adminis-
tration of sorifenacin.  She stopped taking both drugs.  
One patient complained of stomach ache,  and she also 
stopped both drugs.
After taking both medications,  17 patients preferred 
solifenacin,  18 preferred mirabegron,  and the others 
hoped for the development of other drugs.  Four 
patients preferred mirabegron due to the side effects of 
solifenacin,  even though solifenacin was effective.  
Patients who hoped for the development of other drugs 
were not satisfied with either treatment.
Discussion
Mirabegron is the first β3-adrenoceptor agonist used 
in clinical practice for the treatment of OAB.  It has a 
mechanism of action different from that of anti-musca-
rinic agents.  Many studies have shown that mirabegron 
exhibits significant efficacy in treating the symptoms of 
OAB,  and that its efficacy is equivalent to that of 
anti-muscarinic agents.  Khaled et al.  reported that 
Bayesian mixed treatment comparisons (MTCs) were 
performed to evaluate drugs for OAB efficacy and toler-
ability [10].  The MTCs showed that mirabegron 50 mg 
was as efficacious as anti-muscarinics in reducing the 
frequency of micturition incontinence and UUI epi-
sodes,  with the exception of solifenacin 10 mg,  which 
was more efficacious than mirabegron 50 mg for the 
improvement of micturition frequency and the fre-
quency of UUI.   This paper also showed that the mean 
change in the baseline number of micturitions for 
solifenacin 5 mg versus mirabegron 50 mg was −0.24 
micturition episodes per day.  The number of UUI epi-
sodes per day was −0.294.  Solifenacin 5 mg treatments 
tended to be more effective than mirabegron 50 mg,  
but the difference was not significant.
Our study also showed that both drugs were effective 
for OAB symptoms,  and the VAS and OABSS scores for 
OAB symptoms after 4 weeks of treatment showed no 
significant differences between group S and group M.  In 
group M,  the OABSS and VAS of urgency after eight 
weeks was significantly improved compared to that after 
four weeks.  On the other hand,  in group S,  there was 
no significant difference in the OABSS or VAS between 
these 2 time points.  When the subjects switched from 
solifenacin to mirabegron,  there was no significant dif-
ference,  but switching from mirabegron to solifenacin 
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Table 3　 Change in dry mouth and constipation from pre- to post- administration and comparisons of degree among the 2 groups
Baseline 4 weeks after 8 weeks after
VAS
S-M 0.0 (0.0-5.0) 0.5 (0.0-10.0) 0.3 (0.0-9.0)
Intra-group 0.028＊ 0.504
Constipation M-S 1.5 (0.0-10.0) 0.3 (0.0-10.0) 1.5 (0.0-10.0)
Intra-group 0.683 0.166
Inter-group 0.197 0.809 0.549
S-M 0.7 (0.0-10.0) 5.0 (0.0-10.0) 2.5 (0.0-9.0)
Intra-group 0.010＊ 0.064
Dry mouth M-S 2.0 (0.0-6.5) 0.0 (0.0-10.0) 3.3 (0.0-10.0)
Intra-group 0.105 0.023＊
Inter-group 0.422 0.001＊ 0.589
Median (min-max).  Intra-group: The changes pre- and post 4W-administration,  post 4W- and post 8W-administration were compared by the 
Wilcoxon singed rank test Inter-group: The changes pre- and post 4W-,  8W-administration were compared in each group by the Mann-
Whitney U test.  ＊p＜0.05.
significantly improved the OABSS.  It was found to be 
more effective to change the medicine from mirabegron 
to solifenacin.
In group S,  it decreased markedly to 4 points of 
OABSS after four weeks,  whereas the OABSS value 
decreased to 6 points in group M,  so it is possible that 
significant changes in the OABSS did not occur easily 
after the change to mirabegron.  If so,  solifenacin may 
have been the more effective drug.  However,  because 
the number of cases was small,  this was impossible to 
determine definitively.  Additionally,  in our study,  
patients switched to the alternative treatment quickly,  
meaning that they had no drug clearance period,  so it is 
possible that the effect of the first drug remained.  Since 
there was no clearance period,  it is possible that the 
effect cannot be accurately evaluated.  However,  this 
situation seems to be similar to the clinical situation.
Mirabegron had lower incidences of dry mouth and 
constipation.  These adverse events are also reported 
with anti-muscarinics,  and indeed they are one of the 
main causes of the treatment discontinuation in patients 
receiving anti-muscarinics.  Hypertension is the most 
commonly reported adverse event in patients treated 
with mirabegron [15].  β3-adrenoceptors are expressed 
in cardiovascular tissues,  and there are concerns that 
treating OAB with β3-adrenoceptor agonists may affect 
the heart and vasculature.  In this study,  there were no 
side effects such as hypertension or cardiovascular dis-
orders.  Gian et al.  reviewed 20 papers,  and they showed 
that the safety of mirabegron for cardiovascular-associ-
ated adverse events appears to be acceptable at the ther-
apeutic doses and comparable with that of anti-musca-
rinic agents [16].  Kobayashi et al.  evaluated the 
comparative efficacy and tolerability of anti-muscarin-
ics and mirabegron as the primary and salvage therapy 
in patients with OAB.  They found that mirabegron 
seems to have priority as an initial therapy with a dis-
tinct efficacy/tolerability balance [17].  In our study,  
mirabegron also improved OAB symptoms and showed 
fewer adverse events than solifenacin during the treat-
ment period.
This study has some limitations.  First,  the number 
of patients was small.  Second,  we did not include a 
placebo control group.  Therefore,  further study is nec-
essary.
Both solifenacin succinate and mirabegron improved 
OAB symptoms.  Switching from mirabegron to 
solifenacin significantly improved the OABSS,  and 
mirabegron showed fewer adverse events than solifena-
cin during the treatment period.  We therefore recom-
mend that mirabegron be prescribed first for OAB 
patients.  When patients are no longer satisfied with 
mirabegron,  solifenacin can be used.
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